A Historic Opportunity: What the Takaichi–Trump Summit Must Deliver for Biotech

This week, Japanese Prime Minister Sanae Takaichi will visit Washington for a summit with President Trump. The meeting represents a pivotal moment for the US-Japan alliance, and for the global biopharmaceutical ecosystem that both countries depend on to drive medical innovation and protect patients.

At Incubate Coalition Japan, we believe the summit is an opportunity to advance a critical but often overlooked agenda: ensuring that the policy environment in Japan supports the development, launch, and fair reimbursement of innovative medicines. We are calling on both governments to make biotech a priority.

The Challenge: Japan's Market Access Environment

Japan is one of the world's largest pharmaceutical markets and home to world-class scientific talent. Yet persistent challenges in Japan's pricing and reimbursement system are creating headwinds for investors and innovators, and, ultimately for Japanese patients.

In recent years, Japan has seen a troubling pattern of price cuts to patented medicines that fails to appropriately account for clinical value or the cost of innovation. Unpredictable pricing decisions undermine investor confidence and discourage capital formation in Japan's life sciences sector. The result has been a growing drug loss problem, where innovative medicines approved elsewhere take years longer to reach Japanese patients, or never arrive at all.

Our network of investors has watched these dynamics with growing concern. Capital is mobile, and when policymakers create inefficient market dynamics, investment flows elsewhere.

What We Hope to See

Ahead of the Takaichi–Trump summit, ICJ is calling on both governments to commit to the following:

Predictable, innovation-friendly pricing and reimbursement. Japan should adopt pricing reforms that appropriately value clinical outcomes and reward genuine therapeutic advances. Market access frameworks should be transparent, evidence-based, and applied consistently. This is essential to reversing the drug loss phenomenon and ensuring Japanese patients benefit from the latest advances in medicine.

Biotech as a pillar of the bilateral economic agenda. The US-Japan economic relationship is deep and multifaceted. Life sciences should be elevated as a core component of trade and investment discussions. Aligning regulatory pathways, enabling greater data sharing, and reducing barriers to cross-border capital flows would benefit innovators and patients on both sides of the Pacific.

Support for early-stage investment ecosystems. Breakthrough medicines begin with venture capital that is motivated to take on high-risk, early-stage investment that takes decades to pay off, if it does at all. For Japan to produce the next generation of transformative treatments, it must build the policy and financial infrastructure to attract and retain that capital.

Looking Ahead

ICJ was founded on the belief that Japan has enormous potential as a life sciences innovation hub, and that realizing that potential requires the right policy environment. We are encouraged that Prime Minister Takaichi has emphasized economic security and growth as central priorities, and we look forward to working with both governments to ensure that biotech is part of that vision.

We welcome the opportunity this summit represents, and we will continue to engage with policymakers in Tokyo and Washington to advance policies that strengthen Japan's innovation ecosystem, attract global investment, and deliver better medicines to patients faster.